spacer
home > epc > summer 2002 > what do european pharmaceutical companies need to know in order to get effective ip protection in the us?
PUBLICATIONS
European Pharmaceutical Contractor

What Do European Pharmaceutical Companies Need to Know in Order to Get Effective IP Protection in the US?

What factors will affect the granting and enforcement of pharmaceutical patents in the US today? This article looks at the opportunities and pitfalls for pharmaceutical companies looking to diversify into the US market.

This article is intended to examine the considerations that European companies need to bear in mind when applying for patents in the US. Firstly, the general differences between the US patent system and the European system are explained. Then, two important areas that European pharmaceutical companies should be aware of before applying for US patents are analysed. The first is the major changes to examination standards for biotech patents in the US that require applicants to pay greater attention to the utility, written description and enablement requirements when seeking a US patent. The second is the change as to what constitutes infringement following Festo.

Technology, especially biotechnology, is only as strong as its patents. The underlying reason why pharmaceutical progress is dependent on intellectual property protection is the staggering cost of drug development. Perhaps in no other industry can an invention that costs so much to discover and develop be copied or reverse-engineered so inexpensively, at a small fraction of the innovator's research and development costs. Without strong patent protection, pharmaceutical companies could not afford the investment needed to conduct this expensive, high-risk research. So what should pharmaceutical companies be doing to ensure that their patent portfolio is as strong as it possibly can be when applying for US patents?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Hilton Lord, Partner at Marks & Clerk

Hilton Lord graduated from Oxford University in 1983 with an Honours Degree in Biochemistry. He spent his first three years in the patent profession with Wellcome, where he was responsible for drafting the original Zidovudine (AZT) patents.

He then moved on to the city firm of Marks & Clerk (the chartered patent and trade mark agents) where he became a Partner in 1992. Hilton specialises in pharma and biotech, and represents a variety of clients, from Japanese pharma giants through to British universities and domestic start-ups.

spacer
Hilton Lord
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo maintains its steady growth.

According to the data obtained by WACD, the international air cargo information provider, in May; Turkish Cargo, the global air cargo brand providing service to 124 countries around the world, increased its tonnage rate by 7.1 percent, and grew substantially across the industry which shrank by 5.1 percent in the global air cargo market.
More info >>

White Papers

The EC Definition of a Nanomaterial - Potential Measurement Methodologies

NanoSight

In October 2011 the European Commission published a definition of Nanomaterials. This move followed more than six years of scientific consideration of the potential toxicological and environmental challenges posed by engineered nanomaterials.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement